Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a ...

Please provide your email address to receive an email when new articles are posted on . FDA has approved a portable device for patients with locally advanced pancreatic cancer. A phase 3 trial showed ...

(RTTNews) - Novocure (NVCR) announced that the U.S. FDA has approved Optune Pax for adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel.

Novocure shares were soaring Thursday after the company said the Food and Drug Administration approved its Optune Pax product to treat people with certain pancreatic cancers. Novocure stock ended ...

Three years after being diagnosed with pancreatic cancer, Jeneen Genna, from East Islip, says the new FDA-approved device to treat pancreatic cancer will help people struggling to survive. "Any ...

In a phase 3 trial, Optune Pax plus gem/nab-pac significantly improved median overall survival to 16.2 months vs 14.2 months with chemotherapy alone. The Food and Drug Administration (FDA) has ...

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and ...